nach oben

Cancer Causes & Control

Erschienen in:

01.12.2007 | Original Paper

IL6 genotypes and colon and rectal cancer

verfasst von: Martha L. Slattery, Roger K. Wolff, Jennifer S. Herrick, Bette J. Caan, John D. Potter

Erschienen in: Cancer Causes & Control | Ausgabe 10/2007

Einloggen, um Zugang zu erhalten

Abstract

Inflammation appears to play a key role in the development of colorectal cancer (CRC). In this study we examine factors involved in the regulation of inflammation and risk of CRC. Data from a multi-center case–control study of colon (N = 1579 cases and N = 1977 controls) and rectal (N = 794 cases and N = 1005 controls) cancer were used to evaluate the association between the rs1800795 and rs1800796 IL6 polymorphisms and CRC. We evaluated the joint effects of IL6 single nucleotide polymorphisms and regular use of aspirin/NSAIDs and vitamin D receptor (VDR) genotype. Having a C allele of the rs1800796 IL6 polymorphisms and the GG genotype of the rs1800795 IL6 polymorphisms was associated with a statistically significantly reduced the risk of colon (OR 0.76 95% CI 0.57, 1.00), but not rectal (OR 1.49 95% CI 1.02,2.16) cancer. Both IL6 polymorphisms were associated with significant interaction with current use of aspirin/NSAIDs to alter risk of colon cancer: individuals with a C allele in either polymorphism who were current users of aspirin/NSAIDs had the lowest colon cancer risk. CRC risk also was associated with an interaction between VDR and IL6 genotypes that was modified by current use of aspirin/NSAIDs. This study provides further support for inflammation-related factors in the etiology of CRC. Other studies are needed to explore other genes in this and other inflammation-related pathways.

Devroede GJ, Taylor WF, Sauer WG, Jackman RJ, Stickler GB (1971) Cancer risk and life expectancy of children with ulcerative colitis. N Engl J Med 285:17–21PubMedCrossRef

Goldgraber MB, Kirsner JB (1964) Carcinoma of the Colon in Ulcerative Colitis. Cancer 17:657–665PubMedCrossRef

Smalley W, Ray WA, Daugherty J, Griffin MR (1999) Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med 159:161–166PubMedCrossRef

Collet JP, Sharpe C, Belzile E, Boivin JF, Hanley J, Abenhaim L (1999) Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer 81:62–68PubMedCrossRef

Marnett LJ (1992) Aspirin and the potential role of prostaglandins in colon cancer. Cancer Research 52:5575–5589PubMed

Bozcuk H, Uslu G, Samur M, Yildiz M, Ozben T, Ozdogan M, Artac M, Altunbas H, Akan I, Savas B (2004) Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy. Cytokine 27:58–65PubMedCrossRef

Mantovani G, Maccio A, Madeddu C, Mura L, Gramignano G, Lusso MR, Mulas C, Mudu MC, Murgia V, Camboni P, Massa E, Ferreli L, Contu P, Rinaldi A, Sanjust E, Atzei D, Elsener B (2002) Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status. Int J Cancer 98:84–91PubMedCrossRef

Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, Huget P, Dirix LY (2003) Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 103:642–646PubMedCrossRef

Gunter MJ, Stolzenberg-Solomon R, Cross AJ, Leitzmann MF, Weinstein S, Wood RJ, Virtamo J, Taylor PR, Albanes D, Sinha R (2006) A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res 66:2483–2487PubMedCrossRef

10.

Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ (2004) C-reactive protein and the risk of incident colorectal cancer. Jama 291:585–590PubMedCrossRef

11.

Helzlsouer KJ, Erlinger TP, Platz EA (2006) C-reactive protein levels and subsequent cancer outcomes: results from a prospective cohort study. Eur J Cancer 42:704–707PubMedCrossRef

12.

Ito Y, Suzuki K, Tamakoshi K, Wakai K, Kojima M, Ozasa K, Watanabe Y, Kawado M, Hashimoto S, Suzuki S, Tokudome S, Toyoshima H, Hayakawa N, Kato K, Watanabe M, Ohta Y, Maruta M, Tamakoshi A (2005) Colorectal cancer and serum C-reactive protein levels: a case–control study nested in the JACC Study. J Epidemiol 15(Suppl 2):S185–S189PubMedCrossRef

13.

Zhang SM, Buring JE, Lee IM, Cook NR, Ridker PM (2005) C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med 142:425–432PubMed

14.

Ferrari SL, Ahn-Luong L, Garnero P, Humphries SE, Greenspan SL (2003) Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab 88:255–259PubMedCrossRef

15.

Bennermo M, Held C, Stemme S, Ericsson CG, Silveira A, Green F, Tornvall P (2004) Genetic predisposition of the Interleukin-6 response to inflammation: implications for a variety of major diseases? Clin Chem

16.

Mohlig M, Boeing H, Spranger J, Osterhoff M, Kroke A, Fisher E, Bergmann MM, Ristow M, Hoffmann K, Pfeiffer AF (2004) Body mass index and C-174G interleukin-6 promoter polymorphism interact in predicting type 2 diabetes. J Clin Endocrinol Metab 89:1885–1890PubMedCrossRef

17.

Slattery ML, Curtin K, Baumgartner R, Sweeney C, Byers T, Giuliano AR, Baumgartner KB, Wolff RR (2007) IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern united states. Cancer Epidemiol Biomarkers Prev 16:747–755PubMedCrossRef

18.

Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102:1369–1376PubMedCrossRef

19.

Theodoropoulos G, Papaconstantinou I, Felekouras E, Nikiteas N, Karakitsos P, Panoussopoulos D, Lazaris A, Patsouris E, Bramis J, Gazouli M (2006) Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer. World J Gastroenterol 12:5037–5043PubMed

20.

Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, Capella G, Canzian F (2003) Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res 63:3560–3566PubMed

21.

Hayes CE, Nashold FE, Spach KM, Pedersen LB (2003) The immunological functions of the vitamin D endocrine system. Cell Mol Biol (Noisy-le-grand) 49:277–300

22.

Froicu M, Weaver V, Wynn TA, McDowell MA, Welsh JE, Cantorna MT (2003) A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol Endocrinol 17:2386–2392PubMedCrossRef

23.

Park K, Woo M, Nam J, Kim JC. Start codon polymorphisms in the vitamin D receptor and colorectal cancer risk. Cancer Letters (in Press, corrected proof)

24.

Kim HS, Newcomb PA, Ulrich CM, Keener CL, Bigler J, Farin FM, Bostick RM, Potter JD (2001) Vitamin D receptor polymorphism and the risk of colorectal adenomas: evidence of interaction with dietary vitamin D and calcium. Cancer Epidemiol Biomarkers Prev 10:869–874PubMed

25.

Ingles SA, Wang J, Coetzee GA, Lee ER, Frankl HD, Haile RW (2001) Vitamin D receptor polymorphisms and risk of colorectal adenomas (United States). Cancer Causes Control 12:607–614PubMedCrossRef

26.

Slattery ML, Yakumo K, Hoffman M, Neuhausen S (2001) Variants of the VDR gene and risk of colon cancer (United States). Cancer Causes Control 12:359–364CrossRef

27.

Wong HL, Seow A, Arakawa K, Lee HP, Yu MC, Ingles SA (2003) Vitamin D receptor start codon polymorphism and colorectal cancer risk: effect modification by dietary calcium and fat in Singapore Chinese. Carcinogenesis 24:1091–1095PubMedCrossRef

28.

Peters U, McGlynn KA, Chatterjee N, Gunter E, Garcia-Closas M, Rothman N, Sinha R (2001) Vitamin D, calcium, and vitamin D receptor polymorphism in colorectal adenomas. Cancer Epidemiol Biomarkers Prev 10:1267–1274PubMed

29.

Whitfield GK, Remus LS, Jurutka PW, Zitzer H, Oza AK, Dang HT, Haussler CA, Galligan MA, Thatcher ML, Encinas Dominguez C, Haussler MR (2001) Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol Cell Endocrinol 177:145–159PubMedCrossRef

30.

Jurutka PW, Remus LS, Whitfield GK, Thompson PD, Hsieh JC, Zitzer H, Tavakkoli P, Galligan MA, Dang HT, Haussler CA, Haussler MR (2000) The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol Endocrinol 14:401–420PubMedCrossRef

31.

http://seer.cancer.gov/publications/ethnicity/colorect.pdf

32.

Slattery ML, Potter J, Caan B, Edwards S, Coates A, Ma KN, Berry TD (1997) Energy balance and colon cancer–beyond physical activity. Cancer Res 57:75–80PubMed

33.

Edwards S, Slattery ML, Mori M, Berry TD, Caan BJ, Palmer P, Potter JD (1994) Objective system for interviewer performance evaluation for use in epidemiologic studies. Am J Epidemiol 140:1020–1028PubMed

34.

Slattery ML, Caan BJ, Duncan D, Berry TD, Coates A, Kerber R (1994) A computerized diet history questionnaire for epidemiologic studies. J Am Diet Assoc 94:761–766PubMedCrossRef

35.

Watanabe E, Hirasawa H, Oda S, Matsuda K, Hatano M, Tokuhisa T (2005) Extremely high interleukin-6 blood levels and outcome in the critically ill are associated with tumor necrosis factor- and interleukin-1-related gene polymorphisms. Crit Care Med 33:89–97; discussion 242–243PubMedCrossRef

36.

Sweeney C, Curtin K, Murtaugh MA, Caan BJ, Potter JD, Slattery ML (2006) Haplotype analysis of common vitamin D receptor variants and colon and rectal cancers. Cancer Epidemiol Biomarkers Prev 15:744–749PubMedCrossRef

37.

Slattery ML KA, Levin TR (1993) Factors associated with colorectal cancer screening in a population-based study: the impact of gender, health care source, and time. Submitted, March 2003.Potter JD, Slattery ML, Bostick RM, Gapstur SM. Colon cancer a review of the epidemiology. Epidemiol Rev 15:499–545

38.

Camp NJ, Slattery ML (2002) Classification tree analysis: a statistical tool to investigate risk factor interactions with an example for colon cancer (United States). Cancer Causes Control 13:813–823PubMedCrossRef

39.

Slattery ML, Samowitz W, Hoffman M, Ma KN, Levin TR, Neuhausen S (2004) Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway. Cancer Epidemiol Biomarkers Prev 13:538–545PubMed

40.

Slattery ML, Curtin K, Wolff R, Ma KN, Sweeney C, Murtaugh M, Potter JD, Levin TR, Samowitz W (2006) PPARgamma and colon and rectal cancer: associations with specific tumor mutations, aspirin, ibuprofen and insulin-related genes (United States). Cancer Causes Control 17:239–249PubMedCrossRef

41.

Ma J, Stampfer MJ, Giovannucci E, Artigas C, Hunter DJ, Fuchs C, Willett WC, Selhub J, Hennekens CH, Rozen R (1997) Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 57:1098–1102PubMed

42.

Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE (2001) Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293:1673–1677PubMedCrossRef

43.

Fang V, Foye WO, Robinson SM, Jenkins HJ (1968) Hypoglycemic activity and chemical structure of the salicylates. J Pharm Sci 57:2111–2116PubMedCrossRef

44.

Graef I, Gibbons DM (1960) Salicylates and carbohydrate metabolism. Diabetes 9:416–418PubMed

45.

Powell ED, Field RA (1966) Studies on salicylates and complement in diabetes. Diabetes 15:730–733PubMed

46.

McRae JR, Chen M, Robertson RP (1980) Improvement of defective insulin responses to glucose, arginine, and beta-adrenergic stimulation in diabetics by sodium salicylate. Adv Prostaglandin Thromboxane Res 8:1287–1289PubMed

47.

Baron SH (1982) Salicylates as hypoglycemic agents. Diabetes Care 5:64–71PubMedCrossRef

48.

Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, Shulman GI (2002) Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 109:1321–1326PubMedCrossRef

49.

Gunter MJ, Canzian F, Landi S, Chanock SJ, Sinha R, Rothman N (2006) Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev 15:1126–1131PubMedCrossRef

50.

Thomas MG, Tebbutt S, Williamson RC (1992) Vitamin D and its metabolites inhibit cell proliferation in human rectal mucosa and a colon cancer cell line. Gut 33:1660–1663PubMedCrossRef

51.

Ogunkolade BW, Boucher BJ, Prahl JM, Bustin SA, Burrin JM, Noonan K, North BV, Mannan N, McDermott MF, DeLuca HF, Hitman GA (2002) Vitamin D receptor (VDR) mRNA and VDR protein levels in relation to vitamin D status, insulin secretory capacity, and VDR genotype in Bangladeshi Asians. Diabetes 51:2294–2300PubMedCrossRef

52.

Rozen F, Pollak M (1999) Inhibition of insulin-like growth factor I receptor signaling by the vitamin D analogue EB1089 in MCF-7 breast cancer cells: A role for insulin-like growth factor binding proteins. Int J Oncol 15:589–594PubMed

53.

Zeitz U, Weber K, Soegiarto DW, Wolf E, Balling R, Erben RG (2003) Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. Faseb J 17:509–511PubMed

54.

Mahon BD, Wittke A, Weaver V, Cantorna MT (2003) The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. J Cell Biochem 89:922–932PubMedCrossRef

55.

Bhalla AK, Amento EP, Clemens TL, Holick MF, Krane SM (1983) Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab 57:1308–1310PubMedCrossRef

56.

Bemiss CJ, Mahon BD, Henry A, Weaver V, Cantorna MT (2002) Interleukin-2 is one of the targets of 1,25-dihydroxyvitamin D3 in the immune system. Arch Biochem Biophys 402:249–254PubMedCrossRef

57.

Yee YK, Chintalacharuvu SR, Lu J, Nagpal S Vitamin D receptor modulators for inflammation, cancer (2005) Mini Rev Med Chem 5:761–778

Titel: IL6 genotypes and colon and rectal cancer
verfasst von: Martha L. Slattery
Roger K. Wolff
Jennifer S. Herrick
Bette J. Caan
John D. Potter
Publikationsdatum: 01.12.2007
Verlag: Springer Netherlands
Erschienen in: Cancer Causes & Control / Ausgabe 10/2007
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-007-9049-x

Springer Medizin

IL6 genotypes and colon and rectal cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2007

Chronic lymphocytic leukemia radiogenicity: a systematic review

Nitrate in public water supplies and the risk of renal cell carcinoma

Pancreatic cancer, animal protein and dietary fat in a population-based study, San Francisco Bay Area, California

Diet and risk of multiple myeloma in Connecticut women

A prospective study on dietary fat and incidence of prostate cancer (Malmö, Sweden)

Occupational exposure to pesticides and risk of hematopoietic cancers: meta-analysis of case–control studies

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie